Arcadia Biosciences, Inc.
RKDA
$0.92
-$0.11-10.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 22.09% | -30.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.09% | -30.80% | |||
| Cost of Revenue | -1.27% | -19.80% | |||
| Gross Profit | 108.33% | -54.07% | |||
| SG&A Expenses | -24.76% | -0.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.44% | -7.25% | |||
| Operating Income | 43.35% | -19.36% | |||
| Income Before Tax | -230.20% | -255.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -228.22% | -256.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -228.22% | -256.07% | |||
| EBIT | 43.35% | -19.36% | |||
| EBITDA | 43.85% | -19.39% | |||
| EPS Basic | -116.19% | -255.53% | |||
| Normalized Basic EPS | -41.21% | -254.61% | |||
| EPS Diluted | -115.83% | -257.68% | |||
| Normalized Diluted EPS | -41.21% | -255.13% | |||
| Average Basic Shares Outstanding | 51.83% | 0.34% | |||
| Average Diluted Shares Outstanding | 51.83% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||